ERBB2 and neoplasm: Although monoclonal antibody therapy targeting HER2 previously failed for PDAC patients9, HER2.CARTs have higher avidity (multivalent versus bivalent) and ability to directly kill tumor cells through cytolytic proteins as opposed to antibody-dependent cellular cytotoxicity through infiltrating immune cells.